Gastric neoplasm

This early-phase trial tests a new drug called AI-061, which combines two immune-boosting antibodies (anti-PD-1 and anti-CTLA-4) into one treatment. The study will enroll 18 adults with advanced solid tumors that have spread or cannot be removed. The main goals are to find a safe…

This study tests whether adding an immunotherapy drug (atezolizumab) to standard chemotherapy and targeted therapy (trastuzumab) can better shrink HER2-positive stomach or gastroesophageal junction cancer before surgery. About 42 adults with advanced but removable tumors will rec…

This study tests whether tailored vitamin and mineral supplements can correct nutrient deficiencies that often follow surgery for esophageal or gastric cancer. Researchers will enroll 107 adults who had either an esophagectomy or a (sub-)total gastrectomy for cancer and show no s…

This phase 3 study tests whether a new combination of two immunotherapy drugs (domvanalimab and zimberelimab) plus chemotherapy works better than the current standard (nivolumab plus chemotherapy) for people with advanced stomach, gastroesophageal junction, or esophageal cancer t…

This trial tests an experimental drug called zanidatamab, which targets HER2, a protein that fuels certain breast and stomach cancers. Researchers give zanidatamab alongside chemotherapy, and sometimes with the immunotherapy tislelizumab, to people with advanced HER2-positive bre…

This trial tests an experimental drug called SNS-101, which targets a protein called VISTA that may help tumors evade the immune system. Researchers give SNS-101 alone or with another immunotherapy, cemiplimab, to adults with advanced solid tumors that have not responded to stand…

This phase 2 study is testing a combination of three drugs—paclitaxel (a chemotherapy), pembrolizumab (an immunotherapy), and olaparib (a targeted therapy)—in 36 adults with advanced gastric or gastroesophageal cancer that has worsened after one prior treatment. The goal is to se…

This large Phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard trastuzumab plus chemotherapy could improve outcomes for people with advanced HER2-positive stomach or gastroesophageal junction cancer. The study enrolled 738 participants …

This study compares 4 months versus 6 months of chemotherapy (capecitabine and oxaliplatin) in 1024 stomach cancer patients who had surgery. The goal is to see if the shorter treatment works just as well to prevent cancer from coming back, while causing fewer side effects. Partic…

This study tested an experimental drug called CBX-12 in 69 adults with advanced solid tumors (like ovarian, lung, breast, or colon cancer) that had stopped responding to standard therapies. The main goals were to check the drug's safety, find the best dose, and see if it could sh…

This early-stage trial is testing an experimental drug called AMG 355, given alone or together with the immunotherapy Keytruda, in 77 adults with advanced solid tumors (like lung, colon, stomach, or melanoma) that have not responded to standard treatments. The main goals are to c…

This trial tests whether adding the immunotherapy drug toripalimab to a standard chemotherapy regimen (FLOT) before surgery can improve outcomes for people with locally advanced gastric cancer. Participants receive four cycles of the combination, then undergo surgery, and are fol…

This phase 2 trial is testing whether a combination of three FDA-approved drugs—oxaliplatin, capecitabine (Xeloda), and cetuximab—can slow tumor growth in people with advanced or metastatic gastric or gastroesophageal cancer that has not been treated with chemotherapy before. The…

This early-stage trial tests a treatment called Anti-CEA CAR-T, which uses a patient's own immune cells modified to recognize and attack cancer cells that carry a protein called CEA. The study enrolls about 110 adults with advanced colorectal, gastric, or other solid tumors that …

This trial investigates a type of immunotherapy called CAR-T cells that are designed to recognize and attack cancer cells carrying a protein called CEA. The study includes adults with advanced gastric, colon, rectal, esophageal, or pancreatic cancer who have not responded to at l…

This early-phase study tested a new treatment using immune cells from cord blood, modified to target a protein called Claudin18.2 found on some cancer cells. Ten adults with advanced stomach or pancreatic cancer who had no other options received these cells to find the safest dos…

This early-stage trial tests a new type of cell therapy called CEA-targeted CAR-T for people with advanced colorectal, esophageal, stomach, or pancreatic cancers that have stopped responding to standard treatments. The therapy involves taking a patient's own immune cells, enginee…

This early-phase trial tested an experimental drug called KVA12123, given alone or with the immunotherapy Keytruda, in 40 adults with advanced solid tumors (like lung, breast, or colon cancer) that had stopped responding to standard treatments. The main goals were to check safety…

This early-phase trial tested a new drug called RO7496353 combined with an immunotherapy (atezolizumab) and sometimes chemotherapy in 102 people with advanced lung, stomach, or pancreatic cancer. The main goal was to check safety and side effects. Researchers also looked at how t…

This phase 2 trial tested personalized immunotherapy combinations for advanced gastric cancer that had worsened after initial chemotherapy. Researchers matched treatments to tumor genetics: patients with certain genetic features received atezolizumab plus ipatasertib, while other…

This phase 2 trial tested a combination of radiation, a targeted drug (olaparib), and an immunotherapy (pembrolizumab) in 9 people with advanced stomach or gastroesophageal junction cancer that had spread. The goal was to see if this approach could shrink tumors that were not dir…

This phase 2 study tested a combination of two drugs, pembrolizumab and ramucirumab, in 26 people with advanced stomach or gastroesophageal junction cancer that had spread. The goal was to see if the combo could shrink tumors or slow the disease. Participants received both drugs …

This phase 3 trial tested whether adding a targeted drug called bemarituzumab to standard chemotherapy helps people with advanced stomach or gastroesophageal junction cancer that has a specific protein (FGFR2b). The study enrolled 547 adults whose cancer could not be removed by s…

This study tested whether adding intravenous (IV) nutrition to standard oral supplements helps patients who had stomach cancer surgery recover better. 55 adults were randomly assigned to get either the combined nutrition or standard care. The main goal was to see if the combo app…

This study tested a new oral drug called HMPL-453 tartrate, either alone or combined with chemotherapy or an immunotherapy (toripalimab), in 190 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see if th…

This study tested a drug called savolitinib in 110 people with advanced stomach or esophagus-stomach junction cancer whose tumors have a specific genetic change (MET gene amplification). The goal was to see if the drug could shrink tumors and how safe it was. Participants receive…

This study tested whether adding the immunotherapy drug spartalizumab to standard chemotherapy (FLOT) helps shrink stomach cancer before surgery and prevent it from coming back. 67 adults with resectable stomach or gastroesophageal junction cancer received the combination before …

This study tested a combination of two drugs, lenvatinib and pembrolizumab, in 611 people with advanced cancers like breast, ovarian, stomach, colorectal, brain, bile duct, or pancreatic cancer that had stopped responding to standard treatments. The goal was to see if the combo c…

This study tested a new drug called PRL3-ZUMAB in 14 people with advanced solid tumors (like stomach or liver cancer) that stopped responding to standard treatments. The drug was given every two weeks to see if it could shrink tumors or stop them from growing. Researchers also lo…

This study tested a mix of three drugs—trastuzumab deruxtecan (a targeted therapy), nivolumab (an immunotherapy), and chemotherapy—in 30 people with untreated HER2-low stomach or gastroesophageal junction cancer. The goal was to first find a safe dose and then see how well it shr…

This completed study by Pfizer tested a biosimilar (a near-copy) of trastuzumab in 8 people with advanced or recurrent HER2-positive gastric cancer that could not be removed by surgery. The goal was to check safety and how well the drug worked in real-world use. Participants rece…

This study tested whether tracking daily steps with a simple pedometer could help identify cancer patients at high risk of being hospitalized during chemoradiotherapy. 40 adults with head and neck, lung, esophageal, or stomach cancer wore a pedometer and received extra support li…

This completed Phase 2 trial tested whether a special DNA-based test could predict how well patients with stomach or rectal cancer respond to immunotherapy (tislelizumab) combined with chemotherapy and/or radiation. 189 adults with advanced cancer participated. The goal was to se…

This completed Phase 2 study tested a combination of chemotherapy (FOLFIRI) and radiation with 5-fluorouracil in 63 patients with gastric cancer. The treatment was given either before or after surgery to remove the tumor. The goal was to see if this approach is feasible and less …

This early-stage study tested a new drug called cabotamig in 33 adults with advanced cancers of the digestive system (like colon, pancreas, or liver) that had stopped responding to standard treatments. The goal was to see if the drug is safe and how it affects the body and tumors…

This phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy before and after surgery helps people with stomach or gastroesophageal junction cancer. Over 1,000 participants received either pembrolizumab plus chemo or placebo pl…

This study tested whether adding the drug pembrolizumab to standard chemotherapy helps Chinese adults with stomach or gastroesophageal junction cancer. Participants received the drug combination or a placebo before and after surgery. The goal was to see if the combination improve…

This phase 2 study tested a combination of two drugs, TAS 102 (Lonsurf) and ramucirumab (Cyramza), in 23 patients with advanced stomach or gastroesophageal junction cancer that had stopped responding to other treatments. The goal was to see if the combo was safe and could help pa…

This study tested whether a longer intestinal bypass during stomach cancer surgery improves diabetes control better than the standard method. It included 94 adults with early-stage gastric cancer and type 2 diabetes. Researchers measured blood sugar and hormone levels one year af…

This large Phase 3 trial tested adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy for people with advanced stomach cancer that cannot be removed by surgery. Over 1,500 participants received either pembrolizumab plus chemo or a placebo plus chemo. The…

This trial tested a new approach for people with advanced gastrointestinal cancers that had stopped responding to standard treatments. Doctors removed immune cells from patients' tumors, used CRISPR gene editing to disable a gene called CISH, and then infused the modified cells b…

This study compared two types of surgery for stomach cancer: laparoscopic (keyhole) and open surgery. The goal was to see if keyhole surgery leads to a shorter hospital stay and fewer complications. The trial included 210 patients with resectable stomach cancer and is now complet…

This early-phase study tested a new drug called SHR-A1811 in 101 people with advanced stomach or colorectal cancers that have a specific protein called HER2. The main goals were to check the drug's safety, find the best dose, and see early signs of tumor shrinkage. Participants h…

This study tested two drugs, olaparib and ramucirumab, in 51 people with advanced stomach or gastroesophageal junction cancer that had spread or could not be removed. The goal was to find the best dose and see how well the combination worked. The trial is complete, and results ma…

This early-phase trial tested a new drug called SNB-101 in 21 people with advanced solid tumors (like colorectal, breast, and lung cancers) that had stopped responding to standard treatments. SNB-101 is a nanoparticle version of SN-38, the active part of a common chemotherapy dru…

This early-phase trial tested a new drug called CUE-102 in 42 adults with certain advanced cancers (colorectal, gastric, pancreatic, or ovarian) that had returned or spread despite prior treatments. The drug is designed to help the immune system attack cancer cells that carry a s…

This completed study in Laos tested over 1,200 adults for H. pylori, a stomach bacteria linked to cancer. Those infected received a 14-day course of antibiotics and acid-reducing medication. The study also screened high-risk participants for early signs of stomach cancer. The goa…

This study tested a new treatment combination (GEN-001 plus avelumab) in 42 people with advanced stomach or gastroesophageal junction cancer that had not responded to at least two prior therapies. All participants had a specific marker (PD-L1 positive) on their tumors. The goal w…

This phase 2 trial tested a combination of two drugs—telatinib (a pill that blocks tumor blood vessels) and Keytruda (an immunotherapy that helps the immune system attack cancer)—in 16 people with advanced stomach, gastroesophageal junction, or liver cancer. The goal was to see i…

This study tested whether adding radiation to chemotherapy before surgery improves outcomes for people with locally advanced stomach or gastroesophageal junction cancer. About 204 adults with operable tumors received either chemotherapy alone or chemotherapy plus radiation before…

This phase 2 trial tested a combination of two chemotherapy drugs (capecitabine and oxaliplatin) plus two targeted antibodies (bevacizumab and trastuzumab) in 37 people with HER2-positive stomach or esophageal cancer that had spread. The goal was to see how safe and effective the…

This study tested a combination of two drugs, crizotinib and fulvestrant, in 33 people with advanced lobular breast cancer that had lost a protein called E-cadherin. It also tested crizotinib alone in people with diffuse gastric cancer, triple-negative lobular breast cancer, or o…

This study tested a combination of an oral bacterial product (VE800) and the immunotherapy drug nivolumab in 56 people with advanced or metastatic cancers like melanoma, stomach, and colorectal cancer. The goal was to see if the bacteria could help the immune system fight tumors …

This study tested a doctor-designed dose adjustment algorithm to prevent unplanned delays in FOLFOX chemotherapy for people with cancers of the colon, stomach, esophagus, and other digestive organs. 52 adults participated, and the goal was to see if the algorithm could keep treat…

This study tested a new drug called SAR444245 combined with other cancer treatments in 138 adults with advanced gastrointestinal cancers, including esophageal, stomach, liver, and colorectal cancer. The goal was to see if the combination could shrink tumors. The study is complete…

This study tested a new treatment for stomach cancer that has spread to the lining of the abdomen. The approach combines standard chemotherapy with a procedure called PIPAC, which delivers chemotherapy as a pressurized aerosol directly into the abdomen during a keyhole surgery. T…

This phase 2 study tested a new drug, FLX475, combined with the immunotherapy pembrolizumab (Keytruda) in 20 people with advanced or metastatic stomach cancer. The goal was to see if the combination could shrink tumors in patients who had already tried other treatments. The study…

This Phase 3 trial tested whether adding the immunotherapy drug camrelizumab to standard chemotherapy, followed by camrelizumab plus the targeted drug apatinib, helps people with advanced stomach or gastroesophageal junction cancer live longer. The study enrolled 885 participants…

This study tested a new drug called zanidatamab (ZW25) combined with standard chemotherapy in 74 people with advanced HER2-positive cancers of the stomach, bile duct, or colon. The goal was to see if the combination is safe and shrinks tumors. Results will help decide if larger s…

This study tested an experimental drug called ESG401 in 156 people with advanced solid tumors (including breast, lung, and colorectal cancers) who had no other treatment options. The goal was to check the drug's safety, find the right dose, and see if it could shrink tumors. The …

This pilot study tested a new radioactive tracer called 89Zr-DFO*-trastuzumab in 6 people with HER2-positive breast or gastric cancer. The tracer is designed to attach to HER2 proteins on cancer cells and show up on PET scans. Participants received one injection and had up to 4 P…

This completed study looked at whether a special PET scan using 18F-FDG can help doctors more accurately diagnose, stage, and track stomach cancer. Researchers studied 50 patients with confirmed gastric cancer, comparing scan results to other tests. The goal was to see if this im…

This study tested a new radioactive tracer called [18F]FAPI-74 for PET scans in people with gastrointestinal cancers, including liver, bile duct, stomach, pancreatic, and colorectal cancers. The goal was to see if the tracer can accurately detect cancer cells by comparing scan re…

This study tested a new type of PET scan (FAPI) in 20 people with stomach or gastro-esophageal junction cancer. The goal was to see if FAPI scans are more accurate than standard scans for determining the cancer stage before and after chemotherapy. By comparing scan results with t…

This study tested a training system for confocal laser endomicroscopy (CLE), a technique that lets doctors see cells in real time during an endoscopy. 147 patients with stomach lesions were examined by both experts and trainees. The goal was to see if the training helped doctors …

This study tested whether a special endoscopy technique called ME-NBI (magnifying endoscopy with narrow band imaging) can better diagnose early stomach cancer than the standard white light biopsy. Researchers looked at 211 patients with suspicious stomach lesions. They compared t…

Researchers are testing whether a drug called eflornithine can reduce DNA damage in stomach cells that have precancerous changes. The trial enrolls adults aged 30 to 60 with atrophic gastritis or intestinal metaplasia, conditions that raise stomach cancer risk. Participants take …

Researchers at Hanoi Medical University are testing whether personalized meals and diet coaching help stomach and colon cancer patients who are starting chemotherapy. About 120 adults receive tailored menus in the hospital, then learn to prepare high-energy, high-protein diets at…

This study tests whether remimazolam, a newer anesthetic, can reduce the risk of postoperative delirium (sudden confusion) in elderly patients undergoing laparoscopic stomach cancer surgery. Researchers will compare remimazolam to standard anesthesia in 170 patients aged 65 and o…

This study tests whether a conversation game called 'Hello' can help people with cancer and their loved ones discuss advance care planning—decisions about future medical care. Participants will play either the Hello game or a similar conversation game, complete questionnaires, an…

This study is testing whether squeezing a stress ball during chemotherapy can help reduce nausea, anxiety, and fatigue in people with stomach cancer. About 52 adults will take part. Researchers will measure their symptoms during treatment to see if this simple, drug-free tool mak…

This trial compares two minimally invasive surgical techniques for removing the lower part of the stomach in people with gastric cancer: laparoscopy-assisted distal gastrectomy (LADG) and totally laparoscopic distal gastrectomy (TLDG). The goal is to see which approach leads to b…

This study tested whether Phycocare, a supplement made from spirulina, can reduce nerve damage caused by the chemotherapy drug oxaliplatin in people with metastatic gastrointestinal cancers. 73 participants took either Phycocare or a placebo daily for 9 months. The goal was to se…

This study looked at whether placing tiny needles under the skin (intradermal needle therapy) can reduce pain after a stomach procedure called endoscopic submucosal dissection (ESD). 76 patients were randomly assigned to receive either standard care or standard care plus the need…

This study tested a new way to remove early-stage stomach cancer using a special knife that sprays water to help cut and seal tissue at the same time. The goal was to see if this method (called SPEED) is faster and safer than the usual procedure. The study involved 548 adults wit…

This phase 2 trial looked at whether adding acupuncture and acupressure to oral cryotherapy (sucking on ice chips) can reduce nerve pain caused by oxaliplatin chemotherapy in people with gastrointestinal cancers. 78 patients were split into two groups: one got cryotherapy alone, …

This study looked at whether having a palliative care team work alongside surgeons improves quality of life for patients with gastrointestinal cancers like pancreatic or liver cancer. About 379 patients and their family members took part. The main goal was to see if this team app…

This study looks at whether a 4-week pre-surgery program of exercise, nutrition advice, and mental support, combined with a standard enhanced recovery plan, can reduce complications after stomach cancer surgery. About 136 patients aged 18-75 who had chemotherapy before surgery wi…

This study tested whether a high-flow nasal cannula (HFNC) can reduce the risk of low oxygen levels during sedated gastrointestinal endoscopy in 80 adults with high-risk obstructive sleep apnea. Participants had a STOP-Bang score of 5 or higher and were undergoing gastroscopy, co…

This study tested a new way to remove early-stage stomach cancer using a special knife that sprays water while cutting. The goal was to make the procedure faster and safer than the standard method. Researchers looked at 548 patients to compare the new water-injecting technique wi…

This study looked at whether taking zinc supplements can improve quality of life for people with advanced gastrointestinal cancers (like stomach, liver, or pancreatic cancer) who are receiving chemotherapy. Seventeen patients participated, and researchers measured their quality o…

This study looked at whether applying a topical diclofenac gel to the hands and feet could prevent or delay hand-foot syndrome in patients with colorectal or gastric cancer taking capecitabine. About 150 patients were observed at two cancer centers in Turkey. The goal was to see …

This study follows up on over 32,900 people from Linxian, China, who took part in a nutritional trial between 1985 and 1991. Researchers are tracking cancer cases and deaths to see if earlier vitamin and mineral supplements had lasting effects. They are also collecting blood samp…

This study collected information from 733 people with a personal or family history of hereditary stomach cancer. The goal was to better understand how these cancers develop and what genes are involved. Participants provided medical history, blood samples, and genetic testing. The…

Researchers at a large hospital in Seoul reviewed records from nearly 33,000 adults who had curative-intent surgery for one of seven cancers in the abdomen or pelvis: pancreatic, gastric, rectal, cervical, endometrial, kidney, or prostate. They grouped patients by whether they re…

This trial tests whether a 15-minute educational video and a list of suggested questions can improve understanding of immunotherapy among patients with advanced cancer and their caregivers. Participants are randomly assigned to receive the educational materials or usual care, and…

This study looks at early gastric cancer, a disease where the tumor is confined to the stomach's inner layers. It asks whether the pre-surgery assessment (clinical staging) matches the actual findings after surgery (pathological staging) in a large group of Western patients. The …

This trial tests whether presenting a cancer screening appointment as a pre-selected default option (opt-out) makes people at high risk for lung or stomach cancer more likely to accept it, compared to a standard opt-in approach. Participants complete an online questionnaire and d…

This study looked at how well a combination of nivolumab (an immunotherapy drug) and chemotherapy works for people with advanced or recurrent stomach cancer who haven't had treatment before. It involved 500 patients in Japan and tracked things like how long the cancer stayed unde…

This study looked at 60 people having stomach cancer surgery to see if adding an epidural to general anesthesia changes how much muscle relaxant is needed and how fast it wears off. Half got general anesthesia alone, half got general anesthesia plus a thoracic epidural. Researche…

This study created a new tool called the SAH Index to fairly evaluate how well hospitals and surgeons perform gastric cancer surgery. Gastric cancer is serious and often requires major surgery, but comparing results is tricky because patients have different health risks. The rese…

This study looked at whether an AI computer program could suggest cancer treatments that match what experts recommend. Researchers reviewed medical records of 30 people with stomach, colon, or pancreatic cancer. They entered key details into the AI and compared its suggestions to…

This completed study tested whether a new biomarker called 'mass response' can predict how well a cancer therapy will work. Researchers collected tumor cells from 72 patients with various cancers through fluid drainage or biopsies. The goal was to see if this biomarker could guid…

This study looked at whether routine blood tests taken before surgery can help predict complications and long-term survival in people with gastric cancer. Researchers analyzed data from 3,400 patients across multiple hospitals. The goal was to create a simple tool that helps doct…

This study looked at whether two simple frailty questionnaires (G8 and VES-13) can predict serious side effects from chemotherapy in people 65 and older with gastrointestinal cancers. Researchers followed 72 patients receiving standard chemotherapy and checked their frailty, nutr…

This completed study looked at 51 adults with stomach cancer in Portugal to see how many carry inherited gene changes linked to the disease. Researchers used a multigene panel test to check for these mutations. The goal was to understand how common these genetic factors are in th…

This study looked at 43 patients who had stomach tumors removed through a scope (no large cuts). Doctors used special clips to stitch the wound closed. The goal was to see if the clips could fully close the hole and how long the procedure took. Results help improve this minimally…

This study looked at people with advanced solid tumors (like lung, bladder, or melanoma) who had been on immunotherapy for one year and whose disease was stable. Half stopped treatment and half continued. The goal was to see if stopping early affected how long until the cancer pr…

This study looked back at medical records of 260 adults in China with advanced stomach or gastroesophageal junction cancer who received nivolumab as their first treatment. The goal was to see how well the drug worked in everyday practice and what treatment patterns were used. No …

This completed study from Fudan University used a deep learning model to predict whether stomach cancer will come back after surgery. Researchers analyzed data from 5,000 patients across multiple hospitals in Eastern Asia. The model showed strong ability to identify early recurre…

This study tested whether an automated system can grow cancer cells from patient samples (blood, fluid, or tumor tissue) inside chicken eggs. Researchers aimed to see if at least half of the samples would successfully grow. The goal is to create a better, cheaper way to study can…

This study tested a risk scoring model to predict whether stomach cancer might spread to the liver after surgery. Researchers followed 120 patients who had their stomach cancer removed to see if the model could accurately identify those at higher risk. The goal is to help doctors…

This study tested over 1,000 people in Bhutan for H. pylori, a stomach infection that can lead to stomach cancer. Researchers measured infection rates and stomach damage to understand the problem and plan a national prevention program. Participants were from rural villages, and t…

This study looked at over 8,500 people with stomach cancer in Brandenburg, Germany, from 2000 to 2020. Researchers wanted to understand how the disease and survival differ between men and women. They used cancer registry data to analyze these differences, without giving any new t…

This completed study looked at 179 patients with advanced stomach cancer who had chemotherapy and surgery. Researchers used CT scans and genetic data from tumors to build a model that predicts how long patients might stay cancer-free. The goal was to improve survival predictions,…

This study tested a risk scoring model that predicts whether stomach cancer has spread to nearby lymph nodes before surgery. Researchers looked at data from 120 patients who had their stomach cancer removed. The goal was to see if the model could help doctors make better treatmen…